Experimental cancer drug ASP2074 trial halted early
NCT ID NCT05646797
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug called ASP2074 in 23 adults with advanced solid tumors that had spread or couldn't be removed by surgery. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASP2074 (a drug given by IV infusion)
What this could lead to
If this trial had succeeded, it could have pointed toward a new treatment option for people with certain advanced solid tumors who have run out of standard therapies.
What could go wrong
This was a very early (Phase 1) study with only 23 participants, and it was terminated early. It is unknown if ASP2074 is safe or effective, and many early cancer drugs never reach patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center
Nagoya, Aichi-ken, Japan
-
Duke University
Durham, North Carolina, 27710, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
-
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
-
Next Oncology - Oncology
San Antonio, Texas, 78229, United States
-
Osaka International Cancer Institute
Osaka, Japan
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Koto-ku, Tokyo, Japan
-
University of California Davis Health System
Sacramento, California, 95817, United States
-
University of Iowa Hospitals
Iowa City, Iowa, 52242, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States